I undertook my PhD at the University of Leeds from 1999-2002 studing recombinant mycobacterial cancer vaccines and their interaction with dendritic cells and lymphocytes under the supervision of Dr Andrew Jackson and Professor Peter Selby. I then moved to the University of Manchester in 2002 where I began work as a postdoctoral research associate in the group of Professor Robert Hawkins and Dr David Gilham. My work focused on the generation and testing of chimeric antigen receptor (CAR) T-cells targeting CD19 for use in the treatment of B-cell malignancies. This work led to an ongoing Kay Kendall Leukaemia funded Phase I clinical trial testing CD19 CAR T-cells in B-cell lymphoma. In 2009 I joined the Targeted Therapy group led by Professor Tim Illidge and my research has focused on investigating the mechanisms of action of type I and type II anti-CD20 antibodies and improving their efficacy in B-cell malignancies through the use of immunomodulatory agents to enhance adaptive immune responses.

Collaborators and affiliated staff


Memberships of committees and professional bodies

British Society for Immunology

Fellow of the Higher Education Academy


I am a postdoctoral Research Fellow within the Targeted Therapy Group.

I supervise a number of projects within the group looking at combining anti-CD20 mAbs with immuno-modulatory agents to enhance antibody effector mechanisms and the generation of anti-tumour immune responses.

Supervise PhD and undergraduate project students.

Member of the Cancer Research UK Manchester Institute Biosafety Committee.

Unit leader for the MRes Oncology Research Project component.

Sit on the Institute of Cancer Sciences International Student Committee


PhD Cancer Immunology (University of Leeds)

B.Sc (Hons) Biochemistry with Molecular and Cellular Biology (University of Birmingham)

Fellow of the Higher Education Academy

Research interests

My research interests lie in  immunotherapy of B-cell malignancies. I am particularly interested in ways to improve the generation of effective anti-tumour T-cell immune responses post anti-CD20 monoclonal antibody therapy. My research currently focuses on a number of ways to improve anti-CD20 mAb therapy such as combining therapy with immunomodulatory agents, radiation and manipulation of the tumour microenvironment. We are particularly interested in enhancing the efficacy of the novel type II anti-CD20 mAb obinutuzumab. I am also interested in adoptive cell therapy, in particular gene modified T-cells expressing CD19 specific chimeric antigen receptors.



Unit leader for the MRes Oncology Research Project components

MRes Oncology Tutorials

MBChB PEP assessment

Supervision of BSc Pathology and MBChB undergratuate research projects

Supervision of PhD students

Sit on the ICS International Student Committee

ID: 338114